CSIMarket
 


Revance Therapeutics Inc   (RVNC)
Other Ticker:  
 

Revance Therapeutics Inc 's Total Debt to Equity

RVNC's quarterly Total Debt to Equity and Total Debt, Equity growth


In IV Quarter 2023 Revance Therapeutics Inc had stockholder deficit.

Within Major Pharmaceutical Preparations industry Revance Therapeutics Inc achieved the lowest Total Debt to Equity in the forth quarter 2023. While total ranking remained the same in the forth quarter 2023 compared to the previous quarter at no. .

Explain Debt to Equity Ratio?
What is the structure of RVNC´s Total Debt?
How valuable is the RVNC´s Equity?


RVNC Total Debt to Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change - - - - -81.6 %
Y / Y Total Debt Change 13.11 % 13.05 % 0.52 % 0.5 % 35.18 %
Total Debt to Equity MRQ - - 14.2 - 30.11
RVNC's Total Ranking # # # # #
Seq. Equity Change - - - - -91.35 %
Seq. Total Debt Change 0.17 % 12.62 % 0.13 % 0.13 % 0.13 %



Total Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Revance Therapeutics Inc 's Equity $ -152 Millions Visit RVNC's Balance sheet
Revance Therapeutics Inc 's Total Debt $ 429 Millions Visit RVNC's Balance sheet
Source of RVNC's Sales Visit RVNC's Sales by Geography


Cumulative Revance Therapeutics Inc 's Total Debt to Equity

RVNC's Total Debt to Equity for the trailling 12 Months

RVNC Total Debt to Equity

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth - - - - -81.6 %
Y / Y Total Debt TTM Growth 13.11 % 13.05 % 0.52 % 0.5 % 35.18 %
Total Debt to Equity TTM - - 9.58 11.76 8.36
Total Ranking TTM
Seq. Equity TTM Growth - - - - -91.35 %
Seq. Total Debt TTM Growth 0.17 % 12.62 % 0.13 % 0.13 % 0.13 %


On the trailing twelve months basis During the 12 months period ending IV Quarter 2023 company had stockholder deficit.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry RVNC recorded the lowest Total Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Debt to Equity Ratio?
What is the structure of RVNC´s Total Debt?
How valuable is the RVNC´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Total Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquityDec 31 2023 MRQ Total DebtDec 31 2023 MRQ Equity

Date modified: 2024-02-29T16:57:27+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com